Dandelion Health

Understanding the broader impact of a new drug class has historically taken many years and significant capital. As a result, much-needed treatments have taken longer than they should to get to patients. We are in a fascinating period when the emergence of the largest drug class we have ever seen is intersecting with rapid advancements in AI. Thanks to Fast Company for publishing an article written by our CEO Elliott Green on how and why these dual trends may lead to an unprecedented rate of innovation in cardiometabolic treatment. https://lnkd.in/gRKwQCSf

According to a study from Deloitte, companies that effectively harness RWD & AI in their drug development process could save up to 60% on costs, while bringing drugs to market 30% faster - let alone the huge impact this will have on patients over time. Big thanks to Michael Munsell, PhD for his recent piece in Pharmacy Times that explores the vital importance of high-quality data validated AI in the future of precision medicine. https://lnkd.in/e7x8QkEy #realworlddata #realworldevidence #lifesciences #healthAI #AI

"AI goes where the evidence is, not where we think the evidence should be." Dandelion CEO Elliott Green recently spoke to Axios Healthcare Editor Tina Reed, sharing his thoughts on how AI is analyzing diagnostics data to transform care. Check out the full story here: https://lnkd.in/e-rtd92t

Understanding the broader impact of a new drug class has historically taken many years and significant capital. As a result, much-needed treatments have taken longer than they should to get to patients. We are in a fascinating period when the emergence of the largest drug class we have ever seen is intersecting with rapid advancements in AI. Thanks to Fast Company for publishing an article written by our CEO Elliott Green on how and why these dual trends may lead to an unprecedented rate of innovation in cardiometabolic treatment. https://lnkd.in/gRKwQCSf

We are growing our engineering team! JD for our next Infrastructure & DevOps role: https://lnkd.in/gxpHPPg4 Please direct your interest to [email protected]. We value structured first principles thinking, strong collaboration and egoless team members.

Many patients using GLP-1s for weight loss stop treatment within a year. Our newly released research study - featured in CNN by Deidre McPhillips - shows that even the patients who received GLP-1 orders for *at least* a year saw mixed results. This suggests that the real-world efficacy of GLP-1s may be more nuanced than what has been seen in clinical trials. Read the full CNN article here: https://lnkd.in/e6QJirD6 We used our recently launched GLP-1 Data Library to conduct one of the largest real-world studies on GLP-1 usage and efficacy to-date. Among other findings, we saw that: - The top 10% of GLP-1 responders lost up to 15% of their weight by 12 months, compared to almost 5% average weight *gain* in the bottom 10% of responders. - Older adults, women, and people who were diagnosed with obesity but not T2 diabetes at the time of GLP-1 initiation experienced the most weight loss over a 12 month period. As demand for GLP-1 soars, and more clinical trials report GLP-1 benefits beyond weight loss (e.g., for heart and liver health), data and research into real-world use and efficacy will be even more important. Thanks to Deidre McPhillips and the researchers Shivaani Prakash, MSc, PhD and Neil Jethani for shedding light on this important topic. To read the full study and download our latest whitepaper, follow the link in the comments.

The impact of GLP-1 utilization represents a complex and growing area of study and opportunity. Many BIG questions could take years to answer in the absence of a truly multimodal real-world clinical dataset. Enter Dandelion Health's new GLP-1 Data Library. The company is now uniquely positioned to deliver insights to answer a myriad of questions related to efficacy, benefits, side effects, and more. Read more from Dandelion below; we're proud to play a role in their ongoing growth and market-changing clinical datasets.

We're hiring our next Chief of Staff! If you are a motivated individual who can execute and problem solve; if you love building culture and improving processes; if you are ready for your next challenge: COME JOIN the best team I’ve seen.  https://lnkd.in/gqRFBxHm Desired location: New York Please direct your interest to [email protected]. We value structured problem solving, strong communication and egoless team members. JD: https://lnkd.in/g7Kpgmzi

Ahead of today's launch of our GLP-1 Data Library, our Co-founder and CEO Elliott Green sat down with Heather Landi at Fierce Healthcare to discuss how Dandelion's Real World Data and Clinical AI platform can help accelerate answers to the many open questions surrounding GLP-1 usage and impact - and advance precision medicine. Read more in the article below 👇 https://lnkd.in/ddYFbKSB

Today we officially launch our GLP-1 Data Library - the first truly multimodal real-world clinical dataset built specifically to surface insights and opportunities related to GLP-1 usage and impact. GLP-1 receptor agonists are poised to become the biggest drug class of all time. We’ve seen the promising impact of these drugs across obesity and diabetes and their potential to improve the lives of millions of patients. Yet, the more these drugs make their way into routine healthcare, the more open questions we have regarding their impact. - Are they effective for everyone? - Are there other potential benefits outside of obesity and diabetes? - Are there potential unwanted side effects? Historically, answering these questions has taken decades and billions of dollars. The team at Dandelion has spent the past year building one of the most comprehensive real-world datasets on GLP-1 usage and impact to help accelerate the answers to these questions - and more. What makes this dataset different? 🎯 The library goes clinically deep: drawing in imaging, waveforms, notes, pathology, and videos linked to long-term outcomes from the electronic health record to see the efficacy of GLP-1s head-to-head. 🎯 The library is enriched with clinical labels and biomarkers derived from validated machine-learning models to evaluate the quality of weight loss (changes in muscle vs fat) — not just changes in BMI. 🎯 The library is comprehensive so you can see GLP-1's therapeutic effects beyond current uses (obesity, T2DM), including secondary benefits; and 🎯 The library is representative of the US patient population, so you can build precision medicine tools that match patients to the right treatment plans. Read our press release to learn more: https://lnkd.in/dn3q-unt #GLP1 #pharma #clinicaltrials #pharmaAI #realworlddata